BLSM earnings analysis
What we found in BLSM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BlossomHill reported Q2 2026 EPS of $(8.75), substantially worse than the $(0.77) consensus estimate, while revenue and detailed income-statement trend data were not disclosed in the provided filing text. The August IPO generated approximately $151.7 million of net proceeds, lifting cash resources to an estimated runway into Q2 2028, but the company remains loss-making, with a six-month net loss of $44.8 million and accumulated deficit of approximately $179.8 million. The pipeline has regulatory momentum, including Fast Track and orphan drug designations, but remains early-stage and exposed to clinical, safety, financing and manufacturing risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- IPO materially strengthens liquidity
- The company reported Q2 2026 EPS of $(8.75), materially below the $(0.77) consensus estimate. Revenue was not disclosed in the provided filing text.
- $151.7M of net IPO proceeds
- BlossomHill received aggregate gross IPO proceeds of approximately $168.3 million and net proceeds of approximately $151.7 million after $16.6 million of offering expenses.
- Runway extends into Q2 2028
- As of June 30, 2026, cash and cash equivalents totaled $95.4 million. Management estimates existing cash plus IPO proceeds will fund operations into Q2 2028.
- Regulatory designations advance pipeline
- BH-30236 received FDA orphan drug designation for AML in March 2026, while BH-30643 received FDA Fast Track designation in August 2026 for EGFR C797S-positive NSCLC.
- Pipeline remains focused and early-stage
- The company had 69 full-time employees as of June 30, 2026, supporting development of two clinical-stage candidates and one preclinical pan-KRAS candidate.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses remain substantial and rising
- The company reported a six-month 2026 net loss of $44.8 million and an accumulated deficit of approximately $179.8 million as of June 30, 2026. It anticipates substantial and increasing losses for the foreseeable future.
- Clinical pipeline is early-stage
- BlossomHill has not completed any pivotal or late-stage clinical trials and has no product candidates approved for commercial sale. BH-30643 and BH-30236 remain in early clinical development, while BH-501284 is preclinical.
- Additional financing remains necessary
- Management states that additional capital will be required to complete clinical development, despite estimating current resources fund operations into Q2 2028. Future equity financing could dilute holders, while failure to raise capital could delay, reduce or terminate development programs.
- Clinical safety risks could delay trials
- The company reported treatment-related toxicities in ongoing trials, including high-grade EGFR wild-type toxicity, liver-function abnormalities and pneumonitis for BH-30643, and high-grade diarrhea and grade 2 differentiation syndrome for BH-30236.
- China-linked supply chain exposure
- The company relies on third-party manufacturers and currently has no long-term commitments or supply agreements with them. APIs for BH-30643 and BH-30236 are manufactured in China, creating exposure to supply disruptions, tariffs and trade restrictions.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-8.75
What they said about what is next.
No explicit numeric revenue or EPS guidance was provided. Management estimates that cash and cash equivalents of $95.4 million as of June 30, 2026, together with $151.7 million of net IPO proceeds, will fund projected operating expenses and capital expenditures into the second quarter of 2028.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BLSM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever